Brumm Joshua T 4

What Happened

• Joshua T. Brumm, CEO of Crescent Biopharma (CBIO), reported the sale of 42,305 shares on 2026-06-22. The shares were disposed at a weighted average price of $17.99 for total proceeds of $761,067. This was a sale (not a purchase) and was executed to satisfy tax withholding obligations related to the settlement of restricted stock units.

Key Details

• Transaction date: 2026-06-22 (reported on Form 4 filed 2026-06-23).
• Transaction type/code: Sale (S).
• Shares sold: 42,305; weighted average price: $17.99; price range: $16.88–$18.86.
• Total proceeds: $761,067.
• Footnotes: Sales were automatic to cover tax withholding for RSUs granted on Dec 15, 2025 and Mar 17, 2025; executed pursuant to a Rule 10b5-1 plan adopted Feb 28, 2026 (stated purpose: cover taxes). The filer can provide per-price breakdowns on request.
• Shares owned after transaction: Not disclosed in the provided filing.

Context

• These sales were described as routine tax-withholding transactions tied to vested RSUs and executed under a pre-established 10b5-1 plan, which typically indicate administrative need rather than an immediate signal of the insider’s view on the stock. The filing was submitted the day after the transaction, indicating timely reporting.